France· FR:61711184
RIVAROXABAN VIATRIS 15 mg + 20 mg, comprimé pelliculé
A medicinal product containing rivaroxaban, registered in France by VIATRIS (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RIVAROXABAN
- Manufacturer
- VIATRIS (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930269404plaquettes PVC PVDC aluminium de 49 comprimés (42 comprimés de 15 mg + 7 comprimés de 20 mg) - Kit d’initiationEUR 21.41
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eb8a97b5-0161-4eb0-8de7-0669407eb2b0 GET /v1/drugs/eb8a97b5-0161-4eb0-8de7-0669407eb2b0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61711184",
"date_amm": "2021-11-12",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1588",
"substance": "RIVAROXABAN",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé et comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about rivaroxaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.